Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

< Back to Results

Gastric

Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction

Unique Dataset IDGastric_MerckKG_2008_130ClinicalTrial.gov IDNCT00678535
DownloadableYes
SponsorMerck KGaAData ProviderEMD SeronoTotal Study Enrolled Patients882Comparator (Control) Arm Enrolled Patients436RandomizationYes
Study PhaseClinical Study Phase IIIBlinding MethodOpen Label StudyType(s) of dataOnly comparator arm dataIntervention TypeChemotherapy, DrugDataset TypeOther

Clinical Trial Title

Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction

Trial Summary and Conditions

The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line treatment with capecitabine (Xeloda, X) and cisplatin (P) [XP] chemotherapy regimen has a clinically relevant benefit for subjects with advanced gastric adenocarcinoma including gastroesophageal junction (GEJ) adenocarcinoma, in terms of progression free survival (PFS). Secondary objectives are to assess cetuximab plus XP versus XP alone with respect to overall survival, overall tumor response, quality of life (QoL) and safety.

Data Summary

Control arms data files include medical history, eligibility, demography, efficacy, safety, concomitant medications, quality of life, laboratory assessment

Study Objectives

Primary objective: To demonstrate superiority of XP chemotherapy regimen plus cetuximab versus XP alone as first-line treatment for advanced gastric cancer in terms of PFS Secondary objectives: To assess cetuximab + XP versus XP alone with respect to: OS; overall response; QoL; safety

Outcome Measures

- Progression-free Survival (PFS) - Overall Survival (OS) - Best Overall Response (BOR) Rate - Quality of Life (QoL) Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) - Quality of Life (QoL) Assessed by EuroQol 5Dimensions (EQ-5D) Questionnaire - Safety - Number of Participants With Adverse Events (AEs)

Dataset Linkage

Links to additional datasets associated with this dataset are shown below.

Available Downloads:

To gain access to the data and analytic tools click here.

PROTOCOL: EMR 200048-052_EXPAND_Redacted Clinical Study Protocol.pdf

CRF: EMR200048-052_Expand_SAS annotated eCRF_.pdf

DATA DICTIONARY: Data Dictionary.pdf

DATA (COMPARATOR ARM): EMR200048-052_Expand_Raw Data control arm.zip